Telescope Innovations Corp.

OTC: TELIF · Healthcare · Biotechnology

Canadian filerHQ Vancouver, BCReports USD

#730 of 1,394 Healthcare companies by revenuetop-quartile growth

EA Score

——

FH 51DQ —GM —SS 27

v0.1 · 35/100 weight · pillars only

↑ revenue growth (YoY), Altman-Z · ↓ listing tenure, workforce scale

Methodology →

Revenue TTM

$5.3M

Rev growth YoY (TTM)

+67.2%

Net income (FY)

-$1.1M

Employees

Market cap

$27.8M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$3.4M4.8M CAD2025

Net income-$1.1M-1.6M CAD2025

Operating income-$965.4k-1.3M CAD2025

Total assets$5.3M7.3M CAD2025

Liabilities$3.8M5.3M CAD2025

Equity$1.5M2.0M CAD2025

Revenue trend

FY2020 – FY2025 · USD

FY20

FY21

$468.1k

FY22

$2.1M

FY23

$3.4M

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Telescope Innovations Corp. booked $3.4M in FY2025 revenue, growing 63% year over year — faster than most Healthcare companies we track, at a -32.7% net margin.

Peers · Healthcare

Harvard Bioscience, Inc.58C Rein Therapeutics Inc.36D SCYNEXIS, Inc.61C Cryo-Cell International, Inc.63C

Key facts

CEOHenry Dubina

SectorHealthcare

IndustryBiotechnology

HeadquartersVancouver, BC

ExchangeOTC: TELIF

Employees5

IPO date2022-05-24

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.